Supplementary Methods from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors | Synapse
April 30, 2024Open Access
Supplementary Methods from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Inclusion Criteria, Exclusion Criteria, Dose Limiting Toxicity Criteria for First Cycle